Medicare Drug Price Negotiation Program

The Medicare Drug Negotiation Program (MDPNP) - created under the Inflation Reduction Act - allows Medicare to negotiate prices directly with drug manufacturers for certain high-cost medications. As part of implementing this program, the Centers for Medicare & Medicaid Services (CMS) established the Medicare Transaction Facilitator (MTF), a centralized system that manages essential data exchanges between pharmacies, manufacturers, and Medicare. The MTF ensures pharmacies can securely submit required claims information and receive manufacturer refund payments tied to the MDPNP.

Drugs selected for MDPNP for 2026 include: 

  • Eliquis (apixaban)
  • Enbrel (etanercept)
  • Entresto (valsartan/sacubitrilat)
  • Farxiga (dapagliflozin)
  • Imbruvica (ibrutinib)
  • Januvia (sitagliptin)
  • Jardiance (empagliflozin)
  • Novolog/Fiasp (insulin aspart)
  • Stelara (ustekinumab)
  • Xarelto (rivaroxaban)


To help support the enrollment of pharmacies in Indiana in the new MTF system, CMS is providing shared resources to help provide information and support needed to complete enrollment in the MTF DM.

For a quick overview of the MTF and the role it will play in implementing this program, view this short video: Enroll in the Medicare Transaction Facilitator (MTF).

If you are going to participate in any Medicare Part D network for next year, you must enroll in the MTF Data Module (MTF-DM) to receive your manufacturer refund payments. We encourage you to become familiar with the process before enrolling.

Here are some things to know:

  • You can view a FAQ from CMS on the MTF here.
  • You can contact CMS at MFPMedicareTransactionFacilitator@cms.hhs.gov with any questions.
  • Before enrollment, you should make sure your NCPDP profile is accurate and updated.
  • Before enrollment, pharmacies need to know which functions, such as central pay or reconciliation services, they want to assign to any third-party support entities such as PSAOs or reconciliation vendors.
  • During enrollment, pharmacies will need to sign a legal agreement, so proceed with caution and be sure to carefully review and have your legal counsel review.
  • During enrollment, identify as having “material cashflow concerns,” as manufacturers can provide pharmacies with a plan for mitigating their cashflow concerns.
We strongly urge you to enroll before Jan. 1, 2026, though there is no hard deadline to complete enrollment (it will be ongoing to accommodate new pharmacies, for example). It will take approximately one hour and you will have to provide banking information.

Resources for Pharmacies:



Our Mission:

To be the voice and advocate for the profession of pharmacy in Indiana.

Our Vision:

To lead the advancement of Indiana Pharmacy by promoting legislation and innovations that optimize patient care, safety, and the health of our communities.